Business
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France Full commercial launch of
About this update from Insulet Corporation
[{"type":"text","content":"\n\nOmnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France\n\n\n\nFull commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S.\n\n\n\nOmnipod 5 App for iPhone begins limited market release in the U.S.\n\n\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as the limited market release of the Omnipod 5 App for iPhone.\n\n\n“Achieving these milestones demonstrates our Company’s ongoing commitment to making our life-changing diabetes technology more accessible around the world,” said Jim Hollingshead, President and Chief Executive Officer. “With our recent expansion into France, Omnipod 5 is now accessible to the majority of our European customers. The integration of Dexcom G7 and the iPhone mobile app in the U.S. enables more options for those considering Omnipod 5 for their insulin delivery.”\n\n\nOmnipod 5, the #1 prescribed and #1 favorite pump1 in the U.S., is the first tubeless AID system that communicates with a continuous glucose monitor (CGM) and proactively corrects for highs and protects against lows, day and night. The waterproof2 Pod and mobile app control have been designed with the customer in mind aiming to deliver exceptional ease of use. Omnipod 5 has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia.3,4\n\n\nOmnipod 5 is Now Available in France\n\n\nOmnipod 5 is now available in France to people with type 1 diabetes, ages two years or older, and is compatible with the Dexcom G6 CGM. Omnipod 5 recently received reimbursement status from the French National Authority for Health (Haute Autorité de Santé or HAS), making the system accessible to eligible people with type 1 diabetes.\n\n\n“Omnipod 5 has already had a huge impact on health outcomes for those with type 1 diabetes. Today, we cele...